Effect of mitomycin C, verapamil, and hyperthermia on human gastric adenocarcinoma.

abstract：:The cytotoxic effects of ketoconazole, an antifungal agent known to have some activity against human prostate cancer, adrenal cancer, and male metastatic breast cancer, were evaluated using colony-growth and clonogenic assays in eight malignant cell lines. The cytotoxicity of ketoconazole showed a dose- and time-depen...

journal_title：Cancer chemotherapy and pharmacology

authors： Rochlitz CF,Damon LE,Russi MB,Geddes A,Cadman EC

更新日期：1988-01-01 00:00:00

abstract：:A patient with acute nonlymphoblastic leukemia in relapse and anthracycline cardiomyopathy was treated with AMSA in combination with cytosine arabinoside and thioguanine (AAT). Induction of remission was accomplished after one course of therapy without development of congestive heart failure. Radionuclide studies done...

journal_title：Cancer chemotherapy and pharmacology

authors： Fanucchi MP,Arlin ZA

更新日期：1982-12-01 00:00:00

abstract：INTRODUCTION:Despite the extensive clinical experience with irinotecan, significant concerns remain regarding its toxicity. In a phase I trial, we modulated irinotecan pharmacokinetics by inhibiting biliary excretion of SN-38, the active metabolite of irinotecan, using cyclosporine. The modulation appeared to decrease ...

journal_title：Cancer chemotherapy and pharmacology

authors： Desai AA,Kindler HL,Taber D,Agamah E,Mani S,Wade-Oliver K,Ratain MJ,Vokes EE

更新日期：2005-10-01 00:00:00

abstract：:Epirubicin (4'-epidoxorubicin), an analogue of doxorubicin (Adriamycin), has established activity in the treatment of small-cell lung cancer (SCLC) when used at doses of 75 to 120 mg/m2 in previously untreated patients. We completed a phase II study of epirubicin (85 mg/m2 given intravenously at 3-week intervals) in 2...

journal_title：Cancer chemotherapy and pharmacology

authors： Rosenthal M,Kefford R,Raghavan D,Stuart-Harris R

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:To investigate the synergistic cytotoxicity of TRAIL in combination with chemotherapeutic agents in A549 cell lines, we systematically evaluated the cytotoxicity of TRAIL alone and TRAIL in combination with cisplatin, paclitaxel (Taxol) or actinomycin D in A549 cell lines in vitro and in vivo, and whether the s...

journal_title：Cancer chemotherapy and pharmacology

authors： Fan QL,Zou WY,Song LH,Wei W

更新日期：2005-02-01 00:00:00

abstract：PURPOSE:Eltrombopag is indicated in patients with severe aplastic anemia (SAA) refractory to prior immunosuppressive therapy. The combination of eltrombopag and immunosuppressive therapy (such as cyclosporine) is currently being evaluated in patients with treatment-naive SAA. Cyclosporine is a human breast cancer resis...

journal_title：Cancer chemotherapy and pharmacology

authors： Aslanis V,Zhang J,Lomeli B,Grosch K,Ouatas T

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:Abiraterone became a standard hormonal therapy for patients with metastatic castration-resistance prostate cancer (mCRPC). However, patients may experience primary resistance to treatment. To date, few predictive biomarkers of efficacy have been identified. Our aim was to investigate the association between ...

journal_title：Cancer chemotherapy and pharmacology

authors： Crucitta S,Del Re M,Paolieri F,Bloise F,Sbrana A,Sammarco E,Mercinelli C,Cucchiara F,Fontanelli L,Galli L,Danesi R

更新日期：2020-10-01 00:00:00

abstract：:AspCNU and SarCNU are two amino acid amide congeners (L-asparaginamide and sarcosinamide congeners) of chloroethylnitrosoureas. The in vitro myelotoxicity of these agents compared with BCNU at 1-8 micrograms/ml was determined in bone marrow cells from normal volunteers in the CFU-C assay. AspCNU and SarCNU were signif...

journal_title：Cancer chemotherapy and pharmacology

authors： Panasci LC,Dufour M,Chevalier L,Isabel G,Lazarus P,McQuillan A,Arbit E,Brem S,Feindel W

更新日期：1985-01-01 00:00:00

abstract：:The activity of CD437¿6-[3-(1-adamantyl)-4 hydroxyphenyl]-2-naphthalene carboxylic acid¿, a relatively selective activator of RAR-gamma, was evaluated against four human ovarian-carcinoma cell lines : PE01, PE04 (a Pt-resistant in vivo-derived counterpart of PE01), PE01CDDP (a Pt-resistant in vitro-derived model of PE...

journal_title：Cancer chemotherapy and pharmacology

authors： Langdon SP,Rabiasz GJ,Ritchie AA,Reichert U,Buchan P,Miller WR,Smyth JF

更新日期：1998-01-01 00:00:00

abstract：:Pretreatment of the human lymphoblastoid cell line CCRF-CEM with 0.02 microM arabinosyl cytosine (ara C) enhances both the cytotoxic and the DNA-damaging effects of etoposide. This concentration of ara C is itself non-cytotoxic and results in no detectable DNA damage as measured by alkaline elution. Ara C pretreatment...

journal_title：Cancer chemotherapy and pharmacology

authors： Chresta CM,Hicks R,Hartley JA,Souhami RL

更新日期：1992-01-01 00:00:00

abstract：BACKGROUND:Cetuximab and panitumumab are chimeric and fully human monoclonal antibodies, respectively, against epidermal growth factor receptor used in the treatment of metastatic colorectal cancer (mCRC). Incidence of documented infusion reaction (IR) is more common with cetuximab (all grades [g]: 15-21%, g 3/4: 2-5%)...

journal_title：Cancer chemotherapy and pharmacology

authors： Saif MW,Syrigos KI,Hotchkiss S,Shanley J,Grasso J,Ferencz TM,Syrigos K,Shah MM

更新日期：2009-12-01 00:00:00

abstract：:We reviewed 139 resected patients with hepatocellular carcinoma at our clinic between 1963 and 1987, and using the 118 cases for the period between 1963 and 1986, we analyzed the prognostic factors that influenced the long-term prognosis by comparing the survival curves. Significant differences in the survival pattern...

journal_title：Cancer chemotherapy and pharmacology

authors： Kawano N,Ohmori Y,Inoue S,Nagao T,Morioka Y

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:This study was performed to determine the maximum tolerated dose (MTD) and toxicity of vinorelbine when used in combination with doxorubicin and methotrexate with leucovorin rescue in women with metastatic breast cancer. METHODS:Enrolled in the study were 23 women with metastatic breast cancer who had not rece...

journal_title：Cancer chemotherapy and pharmacology

authors： Subramanyan S,Abeloff MD,Bond SE,Davidson NE,Fetting JH,Gordon GB,Kennedy MJ

更新日期：1999-01-01 00:00:00

abstract：:Cytidine analogues such as cytosine arabinoside, gemcitabine, decitabine, 5-azacytidine, 5-fluoro-2'-deoxycytidine and 5-chloro-2'-deoxycytidine undergo rapid catabolism by cytidine deaminase (CD). 3,4,5,6-tetrahydrouridine (THU) is a potent CD inhibitor that has been applied preclinically and clinically as a modulato...

journal_title：Cancer chemotherapy and pharmacology

authors： Beumer JH,Eiseman JL,Parise RA,Florian JA Jr,Joseph E,D'Argenio DZ,Parker RS,Kay B,Covey JM,Egorin MJ

更新日期：2008-08-01 00:00:00

abstract：PURPOSE:Preclinical research and prior clinical observations demonstrated reduced toxicity and suggested enhanced efficacy of cisplatin due to folic acid and vitamin B12 suppletion. In this randomized phase 2 trial, we evaluated the addition of folic acid and vitamin B12 to first-line palliative cisplatin and gemcitabi...

journal_title：Cancer chemotherapy and pharmacology

authors： van Zweeden AA,van Groeningen CJ,Honeywell RJ,Giovannetti E,Ruijter R,Smorenburg CH,Giaccone G,Verheul HMW,Peters GJ,van der Vliet HJ

更新日期：2018-07-01 00:00:00

abstract：PURPOSE:In vitro and in vivo preclinical models have demonstrated synergistic activity when topoisomerase I and II inhibitors are administered sequentially. Topoisomerase I inhibitors increase topoisomerase II levels and increase cell kill induced by topoisomerase II poisons. We evaluated this hypothesis in a cohort of...

journal_title：Cancer chemotherapy and pharmacology

authors： Dowlati A,Levitan N,Gordon NH,Hoppel CL,Gosky DM,Remick SC,Ingalls ST,Berger SJ,Berger NA

更新日期：2001-01-01 00:00:00

abstract：PURPOSE:Irofulven (MGI 114, NSC 683863) is a semisynthetic derivative of illudin S, a natural product present in the Omphalotus illudins (Jack O'Lantern) mushroom. This novel agent produces DNA damage, that in contrast to other agents, is predominately ignored by the global genome repair pathway of the nucleotide excis...

journal_title：Cancer chemotherapy and pharmacology

authors： Kelner MJ,McMorris TC,Rojas RJ,Estes LA,Suthipinijtham P

更新日期：2008-12-01 00:00:00

abstract：:The primary development of clinical resistance to 1-beta-D-arabinofuranosyl cytosine (ara-C) in leukemic blast cells is expressed as decreased cellular concentrations of its active anabolite. Correlations exist between the cellular concentrations of 1-beta-D-arabinofuranosyl cytosine 5'-triphosphate (ara-CTP) in leuke...

journal_title：Cancer chemotherapy and pharmacology

authors： Avramis VI,Mecum RA,Nyce J,Steele DA,Holcenberg JS

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:This phase I study was undertaken to evaluate the safety and tolerability of prolonged infusional etoposide, and to evaluate its pharmacokinetic/pharmacodynamic profile in patients with advanced cancer. METHODS:A group of 17 patients received a 7-day infusion of etoposide (schedule A) every 21 days at doses fr...

journal_title：Cancer chemotherapy and pharmacology

authors： Robert F,Chen S,Miller AA,Lee BC,Molthrop DC,Wheeler RH

更新日期：1996-01-01 00:00:00

abstract：:Imatinib is the treatment of choice for FIP1L1-PDGFRalpha (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, bu...

journal_title：Cancer chemotherapy and pharmacology

authors： Breccia M,Cilloni D,Cannella L,Stefanizzi C,Tafuri A,Fama A,Santopietro M,Saglio G,Alimena G

更新日期：2009-05-01 00:00:00

abstract：:Carboplatin is an alternative for cisplatin in the treatment of urothelial cancers. A pharmacologically guided phase I study of carboplatin in combination with methotrexate (30 mg/m2) and vinblastine (4 mg/m2) was conducted in ten patients by increment of the area under the plasma concentration versus time curve (AUC)...

journal_title：Cancer chemotherapy and pharmacology

authors： Chatelut E,Chevreau C,Brunner V,Martinez M,Houin G,Bugat R,Canal P

更新日期：1995-01-01 00:00:00

abstract：OBJECTIVES:To investigate the effects and potential mechanisms of gambogic acid (GA), a naturally occurring anticancer agent, on the expression and regulation of telomerase in human gastric carcinoma cells. METHODS:GA-induced inhibition of cell proliferation was evaluated by the commonly employed MTT assay on two huma...

journal_title：Cancer chemotherapy and pharmacology

authors： Yu J,Guo QL,You QD,Lin SS,Li Z,Gu HY,Zhang HW,Tan Z,Wang X

更新日期：2006-10-01 00:00:00

abstract：BACKGROUND:We wished to define the maximum tolerated dose (MTD), toxicity, and pharmacokinetics of the novel isoflav-3-ene, NV06 (Phenoxodioltrade mark), a compound with a diphenolic structure related chemically and biologically to genistein and flavopiridol. PATIENTS AND METHODS:Twenty-one patients with advanced canc...

journal_title：Cancer chemotherapy and pharmacology

authors： de Souza PL,Liauw W,Links M,Pirabhahar S,Kelly G,Howes LG

更新日期：2006-10-01 00:00:00

abstract：:The pharmakokinetic profiles of intraperitoneally infused platinum analogues were determined in 13 women exhibiting minimal residual disease following surgery and systemic chemotherapy for epithelial ovarian cancer or fallopian tube carcinoma by following the disposition of tracer doses of 195mPt radiolabel. Six patie...

journal_title：Cancer chemotherapy and pharmacology

authors： Lind MJ,Murphy DJ,Sharma H,Tinker N,Smith A,McAuliffe CA,Crowther D

更新日期：1991-01-01 00:00:00

abstract：:Melphalan (L-PAM) pharmacokinetics were investigated in nine ovarian cancer patients before and after cisplatin (DDP) treatment. When L-PAM was given 24 h before DDP, the elimination half-life (t 1/2 beta), plasma clearance (Clp), and volume of distribution (Vd beta) of L-PAM were, respectively: 46.4 +/- 6.7 min, 20.5...

journal_title：Cancer chemotherapy and pharmacology

authors： Zucchetti M,D'Incalci M,Willems Y,Cavalli F,Sessa C

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:Fruquintinib (HMPL-013) is a novel, potent, and highly selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors (1, 2 and 3). This study was conducted to investigate the metabolism, excretion, and pharmacokinetics of HMPL-013 after a single oral dose to healthy Chinese men....

journal_title：Cancer chemotherapy and pharmacology

authors： Zhou S,Shao F,Xu Z,Wang L,Jin K,Xie L,Chen J,Liu Y,Zhang H,Ou N

更新日期：2017-09-01 00:00:00

abstract：PURPOSE:To report population pharmacokinetic (PK) analysis of the phase 1 study (FPA144-001, NCT02318329) and to select a clinical dose and schedule that will achieve an empirical target trough concentration (Ctrough) for an anti-fibroblast growth factor receptor 2b antibody, bemarituzumab. METHODS:Nonlinear mixed-eff...

journal_title：Cancer chemotherapy and pharmacology

authors： Xiang H,Liu L,Gao Y,Ahene A,Macal M,Hsu AW,Dreiling L,Collins H

更新日期：2020-11-01 00:00:00

abstract：:Previously, we showed that 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone (DMC), isolated from the buds of Cleistocalyx operculatus, significantly inhibited the growth of human liver cancer SMMC-7721 cells and could induce SMMC-7721 cells apoptosis in vitro. Here, we report the antitumor effects of DMC in vivo, usi...

journal_title：Cancer chemotherapy and pharmacology

authors： Ye CL,Liu JW,Wei DZ,Lu YH,Qian F

更新日期：2005-05-01 00:00:00

abstract：BACKGROUND:We evaluated the influence of serum cystatin C (CysC) with respect to other glomerular filtration rate (GFR) markers on the treatment effect of everolimus in a phase II study in patients with metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS:Outcomes were from the study's primary analysis. GFR w...

journal_title：Cancer chemotherapy and pharmacology

authors： Bodnar L,Stec R,Dzierżanowska M,Synowiec A,Cierniak S,Kade G,Szczylik C

更新日期：2016-08-01 00:00:00

abstract：PURPOSE:Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma. Results of pharmacokinetic studies indicate that the optimal schedule of ifosfamide should be repeated doses over several days. With the development of 5-day infusion devices, we developed and evaluated a 5-day infusion regimen of ifos...

journal_title：Cancer chemotherapy and pharmacology

authors： Coriat R,Mir O,Camps S,Ropert S,Billemont B,Leconte M,Larousserie F,Anract P,Alexandre J,Goldwasser F

更新日期：2010-02-01 00:00:00